Jyong Biotech Ltd. (NASDAQ:MENS – Get Free Report)’s share price fell 2.2% during mid-day trading on Wednesday. The company traded as low as $1.66 and last traded at $1.74. Approximately 83,211 shares were traded during trading, an increase of 88% from the average daily volume of 44,258 shares. The stock had previously closed at $1.78.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, August 19th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on MENS
Jyong Biotech Stock Performance
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Jyong Biotech stock. StoneX Group Inc. acquired a new position in Jyong Biotech Ltd. (NASDAQ:MENS – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 15,248 shares of the company’s stock, valued at approximately $33,000.
Jyong Biotech Company Profile
Jyong Biotech is a China-based biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for urological diseases. The company’s research approach includes developing drug candidates derived from natural products and traditional Chinese medicine.
Its development pipeline is centered on treatments for conditions affecting the urinary and male reproductive systems, including benign prostatic hyperplasia. Jyong Biotech is a clinical-stage company, and its primary activities include pharmaceutical research, clinical development and the evaluation of potential products for future commercialization.
The company serves the pharmaceutical and healthcare markets in China and is seeking to develop therapies with broader commercial potential.
Further Reading
- Five stocks we like better than Jyong Biotech
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Jyong Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jyong Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
